# Abaloparatide effects on BMD in acetabular regions corresponding to DeLee and Charnley zones in women with postmenopausal osteoporosis

## TL;DR

Abaloparatide increases bone density in specific acetabular regions in postmenopausal women with osteoporosis, potentially reducing fracture risk and surgical complications.

## Contribution

This study is the first to demonstrate abaloparatide's effect on acetabular bone mineral density in DeLee and Charnley zones.

## Key findings

- Abaloparatide significantly increased BMD in all three acetabular zones at 6 and 18 months.
- Mean BMD increases were 8.38% (zone 1), 7.25% (zone 2), and 9.73% (zone 3) at 18 months.
- BMD increases were homogenously distributed, while placebo led to localized bone loss.

## Abstract

Acetabular bone loss in patients with osteoporosis is associated with increased risk of acetabular fragility fractures, significant morbidity, and can increase risk of complications in patients undergoing total hip arthroplasty. The anabolic osteoporosis treatment abaloparatide increases total hip areal bone mineral density (BMD), but its effect on acetabular BMD is unknown.

Anatomical landmarks were identified in DXA scans from a random subgroup of postmenopausal women with osteoporosis (PMO) treated with abaloparatide 80 μg/d or placebo (n = 250/group) from the phase 3 ACTIVE trial to virtually place a hemispherical shell model of an acetabular cup and define regions of interest corresponding to DeLee and Charnley zones 1 (R1), 2 (R2), and 3 (R3). Changes in BMD from baseline at 6 and 18 months were calculated. Statistical significance was tested using a mixed model with repeated measures. Local mean changes in BMD were depicted by alignment of DXA scans via intensity-based registration onto a reference scan.

Abaloparatide significantly increased acetabular areal BMD in all three DeLee and Charnley zones at 6 and 18 months versus placebo. Mean BMD increases with abaloparatide were 8.38 % (R1), 7.25 % (R2), and 9.73 % (R3) at 18 months. BMD increases were homogenously distributed throughout the regions. With placebo, localized losses in BMD were noted after 18 months.

Abaloparatide treatment rapidly and progressively increases BMD in acetabular zones in PMO.

NCT01343004.

Unlabelled Image

•Abaloparatide showed beneficial effects on acetabular bone.•Significant BMD effects were seen in DeLee and Charnley zones at 6 and 18 months.•These findings may have implications for reducing fractures of the acetabulum.•Increasing acetabular BMD is an attractive goal for reducing complications in THA.•Further studies are warranted to investigate these effects on acetabular bone.

Abaloparatide showed beneficial effects on acetabular bone.

Significant BMD effects were seen in DeLee and Charnley zones at 6 and 18 months.

These findings may have implications for reducing fractures of the acetabulum.

Increasing acetabular BMD is an attractive goal for reducing complications in THA.

Further studies are warranted to investigate these effects on acetabular bone.